Early Development Still Driving CRO Performance

Early development services continue to be a sweet spot for contract R&D services. The big question is how soon the impact of early-development candidates will be felt in late development and commercialization.

External Link - article-122722.pdf

Articles in this issue

about 22 years ago

Article

Excel file and formula for Determining Probability of Passing the USP Content Uniformity Test

about 22 years ago

Article

In the Spotlight-September 2004

about 22 years ago

Article

Promoting Quality in Drug Manufacturing

about 22 years ago

Article

Automation in a Digital, Webbed, and Wireless Age

about 22 years ago

Article

September 2004

about 22 years ago

Article

Design of an Aseptic Process Simulation

about 22 years ago

Article

Use of the Bergum Method and MS Excel to Determine the Probability of Passing the USP Content Uniformity Test

about 22 years ago

Article

Characterization of the Performance of Bin Blenders-Part 3 of 3: Cohesive Powders

about 22 years ago

Article

Particulate-Free Pallets

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

AI oncology data, trispecifics, nitrosamine testing: what three new deals mean for CMC and QA teams.

October 23rd, 2026

Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities

BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.

October 22nd, 2026

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 2: CMC and Regulations

Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.

October 22nd, 2026

Ask the Expert: Choosing Ingredient Suppliers

Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.

FDA approves GSK’s bepirovirsen for hepatitis B, putting antisense oligonucleotide scale-up in focus.

October 21st, 2026

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.

OpenAI acquires Orchestra Bio, adding AI agents for drug program coordination to its Rosalind suite.

October 20th, 2026

OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio

OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.